
Commentary|Videos|June 2, 2025
ASCO 2025: Top Data Highlights from 6/2
Author(s)Yan Leyfman, MD, Chandler Park, MD, MSc, FACP
Fact checked by: Kristi Rosa
MedNews Week hosts speak with 8 key opinion leaders at ASCO 2025 about the top data highlights of the day.
Advertisement
On the Clock is a dynamic video series from MedNews Week and OncLive, bringing you rapid-fire insights from top oncology experts at the 2025 ASCO Annual Meeting. In each episode, key opinion leaders share the data they’re most excited about—highlighting the studies, trends, and breakthroughs that could shape clinical practice.
In this episode, hosts Chandler Park, MD, FACP, and Yan Leyfman, MD, spoke with the following key opinion leaders:
- Liz O'Riordan, MD, PhD, FRCS, of Royal Marsden Hospital
- Laila Agrawal, MD, of Norton Cancer Institute
- Debora Barton, MD, of Full-Life Technologies
- Arya Roy, MD, of The Ohio State University Comprehensive Cancer Center–The James
- Kevin Kayvan Zarrabi, MD, MS, FACP, of Sidney Kimmel Comprehensive Cancer Center
- Pashtoon Kasi, MD, MS, of City of Hope
- Ann LaCasce, MD, MMSc, of Dana-Farber Cancer Institute
- Nina Shah, MD, of UCSF Health and AstraZeneca
Advertisement
Related to this article

Robert A. Winn, MD, discussed his path to becoming a physician, scientist, and leader at Fox Chase Cancer Center.

Updated analyses from a phase 2a study suggest durable survival with namodenosen in a subset of heavily pretreated patients with advanced PDAC.

Need a refresh on the current regulatory landscape for GI oncology? We've got you covered. Here's everything that moved the needle across GI malignancies this month.

Toni Choueiri, MD, discusses the clinical significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.

Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.

Zanubrutinib plus R-BAP produced responses in both younger and older patients with previously untreated mantle cell lymphoma.

Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
SERENA-6 Controversies Push the Breast Cancer Field to Consider the Future Role of ctDNA-Guided Treatment Decisions
2
FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC
3
SYNC-T SV-102 Employs Novel Mechanism to Target Immunologically ‘Cold’ Tumors in Advanced Metastatic Prostate Cancer
4
Surgeons, Medical Oncologists, and Radiation Oncologists Debate Current Thresholds for Systemic Therapy in EGFR-Mutated NSCLC
5




